Article

Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial.

Psychopharmacology Research Program, Department of Psychiatry, PO Box 670559, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 06/2005; 66(5):617-24. DOI: 10.4088/JCP.v66n0512
Source: PubMed

ABSTRACT The response of 62 outpatients with DSM-IV bipolar disorders to open-label adjunctive zonisamide was evaluated in a prospective 8-week acute trial, followed by a 48-week continuation trial, conducted from June 2001 through May 2002.
During the acute trial, response to zonisamide was assessed weekly for the first 4 weeks and every 2 weeks for the second 4 weeks with the Clinical Global Impressions scale modified for bipolar illness (CGI-BP), the Young Mania Rating Scale (YMRS), and the Inventory for Depressive Symptomatology (IDS). During the continuation trial, patients were assessed with these scales every 4 weeks. Patients' weights and side effects were also evaluated. Outcome measures were analyzed with repeated-measures analyses of variance.
Patients with manic symptoms at study entry (N = 34) displayed significant reductions in CGI-BP-Mania Severity and YMRS scores in the acute and continuation (N = 19) trials (p values < .0001 and < .001, respectively). Patients with depressive symptoms at study entry (N = 22) showed significant decreases in CGI-BP-Depression Severity and IDS scores in the acute trial (p values < .001 and < .05, respectively), but only 9 patients entered the continuation trial. Among these 9 patients, maintenance of anti-depressant response was mostly maintained. Initially euthymic patients (N = 6) showed no change in any rating scale scores acutely, but 2 of 4 patients who entered the continuation trial developed depressive symptoms. The 62 patients as a group showed significant weight loss in both trials (p values < .001). However, 20 patients (32%) discontinued zonisamide for worsening mood symptoms.
Adjunctive zonisamide was associated with beneficial effects on mood and body weight in some patients with bipolar disorders, but was also associated with a high discontinuation rate due to worsening mood symptoms. Double-blind, placebo-controlled studies are necessary to determine zonisamide's thymoleptic properties, if any, in bipolar disorders.

0 Bookmarks
 · 
134 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Antiepileptic drugs (AE) such as valpro- ate and carbamazepine are today widely used in psychiatry. Recently, lamotrigine has been approved for the prevention of depressive recurrences in bipolar disor- der. Some of the new AEs such as oxcar- bazepine, gabapentin, topiramate, leve- tiracetam, pregabalin and zonisamide have been reported to be effective in the treatment of several resistant mood, anxiety, impulse control, substance use, eating and personality disorders. In the present article we systematically review the available literature on the use of zonisamide in psychiatry. Method Medline, Embase, PsychInfo databases were searched for existing studies of zonisamide in mental, mood, anxiety, and eating disorders. Inquiry to Eisai pharmaceuticals and manual search on significant book chapters and reviews on the same topic were also performed. Results Zonisamide shows an anticonvulsant action in patients with partial, gen- Introduzione eralized and combined seizures. The mechanism of action is not complete- ly known, but zonisamide stabilizes neuronal cell activity and suppresses neuronal hypersynchronization. This mechanism could also be responsible for the antianxiety, antimanic, anti- depressant and anti-impulsive action of the drug. Most clinical studies on zonisamide are open, non-random- ized, and involve small samples; therefore the results should still be considered preliminary (Tab. I). With these limitations, the data reported seem to indicate efficacy of the drug as adjunctive treatment of various treatment-resistant patients with bipo- lar and eating disorders, and obesity. Zonisamide is well tolerated; howev- er drop-out rates are high; most fre- quently reported side effects include somnolence, depression, and cogni- tive disturbances. Conclusion The available information on zonisamide in different mental disorders should be considered preliminary. Although re- ported results are encouraging, further controlled research in larger samples is necessary.
    Giornale Italiano di Psicopatologia 01/2008; 18:316-323.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent research suggests a potential role for a new generation of anticonvulsant drugs, including zonisamide, in the treatment of alcohol dependence. Some elements of the central mechanism of action that zonisamide has in common with ethanol, give rise to the question of whether there is an interaction between these two agents and whether there is any risk associated with the enhanced depressive effect of these agents on the central nervous system.
    Alcohol and alcoholism (Oxford, Oxfordshire). Supplement 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: To clarify the anti-parkinsonian mechanisms of action of zonisamide (ZNS), we determined the effects of ZNS on tripartite synaptic transmission associated with kynurenine (KYN) pathway (KP) in cultured astrocytes, and transmission in both direct and indirect pathways of basal ganglia using microdialysis. Interactions between cytokines [interferon-γ (IFNγ) and tumor-necrosis factor-α (TNFα)] and ZNS on astroglial releases of KP metabolites, KYN, kynurenic-acid (KYNA), xanthurenic-acid (XTRA), cinnabarinic-acid (CNBA) and quinolinic-acid (QUNA), were determined by extreme liquid-chromatography with mass-spectrometry. Interaction among metabotropic glutamate-receptor (mGluR), KP metabolites and ZNS on striato-nigral, striato-pallidal GABAergic and subthalamo-nigral glutamatergic transmission was examined by microdialysis with extreme liquid-chromatography fluorescence resonance-energy transfer detection. Acute and chronic ZNS administration increased astroglial release of KYN, KYNA, XTRA and CNBA, but not QUNA. Chronic IFNγ administration increased the release of KYN, KYNA, CNBA and QUNA, but had minimal inhibitory effect on XTRA release. Chronic TNFα administration increased CNBA and QUNA, but not KYN, KYNA or XTRA. ZNS inhibited IFNγ-induced elevation of KYN, KYNA and QUNA, but enhanced IFNγ-induced that of CNBA. TNFα-induced rises in CNBA and QUNA were inhibited by ZNS. ZNS inhibited striato-nigral GABAergic, striato-pallidal GABAergic and subthalamo-nigral glutamatergic transmission via activation of groups II and III mGluRs. ZNS enhanced astroglial release of endogenous agonists of group II mGluR, XTRA and group III mGluR, CNBA. Activated endogenous mGluR agonists inhibited transmission in direct and indirect pathways of basal ganglia. These mechanisms contribute to effectiveness and well tolerability of ZNS as an adjunct treatment for Parkinson's disease during L-DOPA monotherapy.
    Neuropharmacology 08/2013; · 4.82 Impact Factor

Full-text (2 Sources)

Download
252 Downloads
Available from
May 23, 2014